<DOC>
	<DOCNO>NCT00904371</DOCNO>
	<brief_summary>The study design evaluate effect treatment Micardis/MicardisPlus blood pressure ability reduce different indicated cardiovascular risk . Further , study evaluate current antihypertensive treatment pattern daily practice among patient population increase cardiovascular risk .</brief_summary>
	<brief_title>Evaluation Effect Telmisartan ( Micardis® 80 mg/ MicardisPlus® 80/12.5 mg ) Blood Pressure Cardiovascular Risk Factor Index High Risk Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Inclusion criterion : diagnosis essential arterial hypertension ( BP &gt; 140/90 mm HG BP &gt; 130/80 mm Hg diabetic patient ) least additional cardiovascular risk factor Exclusion criterion : hypersensitivity active substance excipients ACE inhibitor angiotensin receptor blocker ( ARB ) available local market pregnancy lactation diseases involve biliary obstruction severe liver impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>